InflaRx N.V. (IFRX)
Stock Price:
$4.66 USD
-0.06 (-1.27%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
121.65M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-53.25M |
| Shares Out |
26.11M |
| EPS (ttm) |
-1.39 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$4.66 |
| Previous Close |
$4.72 |
| Change ($) |
-0.06 |
| Change (%) |
-1.27% |
| Day's Open |
4.70 |
| Day's Range |
4.54 - 4.73 |
| Day's Volume |
86,219 |
| 52-Week Range |
2.25 - 9.70 |
More Stats
| Market Cap |
121.65M |
| Enterprise Value |
7.01M |
| Earnings Date (est) |
Nov 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
26.11M |
| Float |
19.44M |
| EPS (basic) |
-2.05 |
| EPS (diluted) |
-1.39 |
| FCF / Share |
-1.68 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
465,248 |
| Short Ratio |
0.85 |
| Short % of Float |
2.39% |
| Beta |
0.46 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.15 |
| Revenue |
n/a |
| Operating Income |
-57.08M |
| Net Income |
-53.25M |
| Free Cash Flow |
-43.80M |
| Net Cash |
114.64M |
| Net Cash / Share |
4.39 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-24.60% |
| ROE |
-41.81% |
| ROIC |
-59.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
2 |
| Overweight |
1 |
| Hold |
4 |
| Underweight |
0 |
| Sell |
2 |
Analyst Consensus: Overweight
Price Target
$9.50*
(103.86% upside)
Low
3.50
Current: $4.66
High
19.00
Target: 9.50
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -57.08 | -37.82 | -19.55 | -7.12 | -3.78 |
| Net Income | -53.25 | -29.81 | -24.24 | -8.94 | -4.92 |
| Shares Outstanding | 26.00 | 25.10 | 9.41 | 2.36 | - |
| Earnings Per Share | -2.05 | -1.19 | -2.58 | -3.80 | -2.10 |
| Operating Cash Flow | -43.20 | -21.55 | -12.15 | -4.99 | -3.31 |
| Capital Expenditures | -0.59 | -0.81 | -0.15 | -0.05 | -0.01 |
| Free Cash Flow | -43.80 | -22.36 | -12.30 | -5.05 | -3.32 |
| Cash & Equivalents | 115 | 157 | 123 | 29.12 | 3.30 |
| Total Debt | 0.85 | - | - | - | - |
| Net Cash / Debt | 115 | 157 | 123 | 29.12 | 3.30 |
| Assets | 122 | 159 | 124 | 29.52 | 3.59 |
| Liabilities | 14.43 | 7.82 | 4.78 | 55.21 | 21.21 |
| Book Value | 107 | 151 | 119 | -25.69 | -17.62 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
InflaRx N.V. |
| Country |
Germany |
| Employees |
43 |
| CEO |
Niels Christoph Riedemann |
Stock Information
| Ticker Symbol |
IFRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IFRX |
| IPO Date |
November 8, 2017 |
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.